1, 2-dihydro-2-oxo-1, 8-naphthyridine derivative
View Patent ↗Hydrates of N-[1-butyl-4-[3-[3-(hydroxy)propoxy]-phenyl]-1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl]-N′-(2,6-diisopropyl-4-aminophenyl)urea hydrochloride of the formula: are quite excellent in stability than amorphous one and are more preferable for medicaments.
1. A monohydrate of N-[1-butyl-4-[3-[3-(hydroxyl)propoxy]-phenyl]-1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl]-N′-(2,6-diisopropyl-4-aminophenyl)urea hydrochloride of the formula:
2. The compound according to claim 1 , which has main peaks at the diffraction angles (2θ) of 8.8°, 10.1°, 20.1° and 21.0° in the powder X-ray diffraction pattern.
3. A pharmaceutical composition comprising the compound as set forth in claim 1 or 2 .
4. A method for inhibiting an acyl-CoA: cholesterol acyl transferase (ACAT) in a patient, which comprises administering a therapeutically effective amount of the compound as set forth in claim 1 or 2 to a patient in need.
5. A method for treatment of hyperlipidemia or atherosclerosis, which comprises administering a therapeutically effective amount of the compound as set forth in claim 1 or 2 to a patient in need.